PREM-LC - Patient Reported Experience Measures in Lung Cancer
Research type
Research Study
Full title
PREM-LC: Development and pilot testing of a Patient Reported Experience Measure in Lung Cancer
IRAS ID
183533
Contact name
Janelle Yorke
Contact email
Sponsor organisation
The University of Manchester
Duration of Study in the UK
0 years, 5 months, 30 days
Research summary
Patients' experience of treatment and care is a major indicator of quality and is increasingly used as a metric for quality improvements in healthcare. There has been significant expansion in the development and application of patient reported questionnaires that measure care experiences, termed Patient Reported Experience Measures (PREM). There is no available PREM for patients with Lung Cancer. This study aims to develop and test a PREM in Lung Cancer (PREM-LC) for clinical application.
All patients will be receiving clinical care at The Christie; the study will be conducted in four stages:
Stage I: 20 patients with lung cancer will be asked to participate in face-to-face interviews with the researcher(s) to discuss their experiences of clinical care at The Christie.
Stage II - Items will be extracted from the Stage I to formulate a draft item list. ~7 patients from Stage I will be asked to attend a further face-to-face interview with the researcher(s) to ensure all items are clear and easily understood.
Stage III – A draft PREM-LC will be administered to ~100 patients receiving care at The Christie along with validated patient experience and quality of life questionnaires developed by the European Organisation for Research and Treatment of Cancer (EORTC) IN-PATSAT32 (satisfaction with care), EORTC QLQ-C30 and QLQ - LC13 (quality of life) at baseline (T1). Approximately 50 patients will repeat the draft PREM-LC together with a Global Rating of Change Scale one week later (T2).
Stage IV – We will pilot test the final PREM-LC with 20 patients to assess its feasibility for routine collection of patient experience data.
Eligible patients will fall in to one of the following groups: 1) Patients undergoing treatment with curative intent (concurrent chemo/radiotherapy); 2) Patients undergoing palliative chemotherapy; 3) Patients undergoing palliative radiotherapy; 4) Patients receiving best supportive care undergoing no further anti-cancer treatment.
REC name
Wales REC 5
REC reference
15/WA/0378
Date of REC Opinion
16 Oct 2015
REC opinion
Favourable Opinion